Telix Pharmaceuticals | TLX - 销售收入



金融业
股票价格
AUD
资产
AUD 1.16B
现金及等价物
AUD 207.16M
销售成本
AUD 221.36M
流动资产
AUD 330.28M
流动负债
AUD 231.62M
债务
AUD 418.25M
EBIT
AUD 8.04M
EBITDA
AUD 18.42M
EPS每股收益
AUD -0.05
股本和储备
AUD 416.86M
销售毛利
AUD 217.82M
债务利息支出
AUD 7.62M
利息收入
AUD 1.37M
贷款资金
AUD 448.45M
市值
AUD 5.47B
净收入
AUD -4.83M
营业费用
AUD 405.4M
营业利润
AUD 8.04M
普通股股本
AUD 338.78M
PE价格收益
244.46
税前利润
AUD 76.73M
销售收入
AUD 413.44M
销售和管理费用
AUD 93.48M
股票
AUD 35.23M
贸易债权人
AUD 71.66M
应收帐款人
AUD 135.25M


销售 更改 日
Cochlear AUD 1.18B 590.35M 2025-12
CSL USD 8.33B 4.79B 2025-12
Integral Diagnostics AUD 238.44M 7.19M 2024-06
Mayne Pharma AUD 212.07M 17.03M 2025-12
Medical Developments International AUD 21.57M 12.04M 2025-12
Mesoblast USD 30.3M 0 2026-06
Neuren Pharmaceuticals AUD 42.24M 28.1M 2025-12
Pacific Edge NZD 5.56M 379K 2026-06
Paradigm Biopharmaceuticals AUD 284.06K 292.06K 2025-12
Polynovo AUD 70.33M 35.75M 2025-12
PYC Therapeutics AUD 11.04M 2.44M 2025-12
Ramsay Health Care AUD 9.34B 82.2M 2025-12
ResMed USD 1.43B 8.6M 2026-03
Sonic Healthcare AUD 5.45B 470M 2025-12